Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Clear-cell renal cell carcinoma (ccRCC) is linked to von Hippel-Lindau (VHL) gene inactivation.
• VHL inactivation causes overproduction of vascular endothelial growth factor (VEGF), promoting tumor angiogenesis, growth, and metastasis.
• The mammalian target of rapamycin (mTOR) pathway regulates hypoxia-inducible factor-1 (HIF-1) and VEGF translation.

Purpose of the Study:

• To review current therapeutic strategies targeting key pathways in ccRCC.
• To highlight the role of anti-VEGF and mTOR-targeting agents in ccRCC treatment.
• To emphasize the need for continued clinical trial support for novel ccRCC therapies.

Main Methods:

• Review of existing literature on ccRCC pathogenesis and targeted therapies.
• Analysis of clinical outcomes associated with approved and investigational agents.
• Discussion of emerging therapeutic combinations and future research directions.

Main Results:

• Sunitinib, sorafenib, bevacizumab, and temsirolimus have demonstrated efficacy by inhibiting tumorigenic pathways.
• Other agents, including multitargeted tyrosine kinase inhibitors (lapatinib, axitinib, pazopanib) and lenalidomide, show promise.
• Combinatorial approaches are under investigation to enhance therapeutic effects.

Conclusions:

• Targeted therapies inhibiting VEGF and mTOR pathways have significantly improved ccRCC clinical outcomes.
• A range of multitargeted TKIs and antiangiogenic agents are active in ccRCC.
• Further clinical trials are crucial for evaluating these agents and combinations to advance ccRCC treatment.